These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19995744)

  • 21. [Future aspects of the treatment of pulmonary arterial hypertension].
    Ghofrani HA; Rosenkranz S; Grimminger F
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S338-40. PubMed ID: 17139602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
    Ivan D; Niveiro M; Diwan AH; Eton O; Kim KB; Lacey C; Gonzalez C; Prieto VG
    J Cutan Pathol; 2006 Apr; 33(4):280-5. PubMed ID: 16630177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
    Koon HB; Bubley GJ; Pantanowitz L; Masiello D; Smith B; Crosby K; Proper J; Weeden W; Miller TE; Chatis P; Egorin MJ; Tahan SR; Dezube BJ
    J Clin Oncol; 2005 Feb; 23(5):982-9. PubMed ID: 15572730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Imatinib and solid tumours].
    Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
    Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy.
    Savikko J; Taskinen E; Von Willebrand E
    Transplantation; 2003 Apr; 75(8):1147-53. PubMed ID: 12717194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of chronic graft-versus-host disease with protein tyrosine kinase inhibitors].
    Martínez C
    Methods Find Exp Clin Pharmacol; 2010 Dec; 32 Suppl A():69-71. PubMed ID: 21381292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stimulatory autoantibodies to the PDGF receptor in scleroderma.
    Lozano E; Segarra M; Cid MC
    N Engl J Med; 2006 Sep; 355(12):1278-9; author reply 1279-80. PubMed ID: 16990392
    [No Abstract]   [Full Text] [Related]  

  • 28. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.
    Magro L; Catteau B; Coiteux V; Bruno B; Jouet JP; Yakoub-Agha I
    Bone Marrow Transplant; 2008 Dec; 42(11):757-60. PubMed ID: 18762765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts.
    Mori Y; Ishida W; Bhattacharyya S; Li Y; Platanias LC; Varga J
    Arthritis Rheum; 2004 Dec; 50(12):4008-21. PubMed ID: 15593186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
    Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Imatinib--a new perspective in the treatment of tumors].
    Klener P; Klamová H
    Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis.
    Leipner C; Grün K; Müller A; Buchdunger E; Borsi L; Kosmehl H; Berndt A; Janik T; Uecker A; Kiehntopf M; Böhmer FD
    Cardiovasc Res; 2008 Jul; 79(1):118-26. PubMed ID: 18326555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease.
    Distler JH; Manger B; Spriewald BM; Schett G; Distler O
    Arthritis Rheum; 2008 Aug; 58(8):2538-42. PubMed ID: 18668536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors.
    Maurer B; Distler A; Dees C; Khan K; Denton CP; Abraham D; Gay RE; Michel BA; Gay S; Hw Distler J; Distler O
    Ann Rheum Dis; 2013 Dec; 72(12):2039-46. PubMed ID: 24013728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imatinib mesylate treatment of nephrogenic systemic fibrosis.
    Kay J; High WA
    Arthritis Rheum; 2008 Aug; 58(8):2543-8. PubMed ID: 18668587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R; Kimura S
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term.
    Neef M; Ledermann M; Saegesser H; Schneider V; Widmer N; Decosterd LA; Rochat B; Reichen J
    J Hepatol; 2006 Jan; 44(1):167-75. PubMed ID: 16168515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial.
    Fiorentini G; Rossi S; Lanzanova G; Biancalani M; Palomba A; Bernardeschi P; Dentico P; De Giorgi U
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):17-20. PubMed ID: 16767900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
    Sotlar K
    Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.